A current New England Journal of Medicine study indicates that the use of the PARP inhibitor iniparib in combination with standard chemotherapy to treat metastatic triple-negative breast cancer offers a significant increase in clinical benefit, a measure of durable response or disease stabilization, as well as an increase in progression-free survival.
More...